Clinical

In this episode, 'System-Level Barriers and Evidence Gaps in the Adoption of Emerging MASH Therapies,' the expert hepatologist explored the following questions: What barriers exist to adopting emerging metabolic dysfunction-associated steatohepatitis (MASH) therapies at the system level, and how can they be overcome? What clinical and economic evidence is needed for formulary adoption of new therapies? The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care? What financial and clinical benefits arise from implementing early detection programs for MASH? How does fragmentation within the MASH ecosystem affect value-based care outcomes? How can population health efforts optimize these outcomes?

Welcome back to another AJMC Insights series. In this episode titled, 'The Financial and Clinical Cost of Delayed MASH Detection and Fragmented Care', Dr. Jaideep Behari led the conversation about the following questions: The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care? What financial and clinical benefits arise from implementing early detection programs for MASH? How does fragmentation within the MASH ecosystem affect value-based care outcomes? How can population health efforts optimize these outcomes?

Kirk Campbell, MD, discusses why FSGS is traditionally difficult to treat, the significance of the sparsentan approval, and future access needs.

Financial toxicity independently predicts a lower quality of life for patients with HS, with greater disease severity and biologic use driving the strain.

An investigational coronary IVL catheter achieved high procedural success and favorable safety outcomes in patients with severely calcified CAD.

New data examine switching biologics in severe asthma and inhaled treprostinil's effect on lung function in idiopathic pulmonary fibrosis (IPF).

Poster data show the efficacy of nerandomilast in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis.

Kirk Campbell, MD, sees sparsentan as the beginning of a new treatment era for FSGS, a condition that has lacked approved therapies until now.

After vitiligo diagnosis, many patients remain untreated and switch quickly between therapies, according to new data on treatment patterns.

SUNRISE data showed tezepelumab improved asthma outcomes while reducing steroid dependence in severe asthma.

FVC percent predicted could differ in those with ILD who progress to terminal outcomes, indicating a need for patient monitoring.

Jerry A. Krishnan, MD, PhD, discusses NIH RECOVER findings on long COVID, pulmonary complications, and immune dysfunction at ATS 2026.

SUNRISE trial data showed tezepelumab reduced oral steroid use while maintaining asthma control in severe asthma.

Rising urine albumin signals hidden kidney and heart risk; learn why earlier UACR/eGFR screening and new therapies can change CKD outcomes.

Investigators found major variation in prior authorization rules across commercial insurers, highlighting limited standardization and transparency.

New findings presented at ACC.26 highlight the potential of Lp(a)-targeted therapies for patients with ASVD and elevated Lp(a).

ALIS plus MDT improved symptoms and culture conversion in newly diagnosed MACLD, according to late-breaking data presented at ATS 2026.

A cross-sectional analysis found diverging skin cancer trends by region, with basal cell carcinoma projected to have the highest global burden by 2050.

Patients with IPF hospitalized for CDI had higher mortality, longer stays, and greater costs.

Community oncology grapples with the logistics of bispecifics with step-up dosing straining staff and reimbursement, said Lekan Ajayi, PharmD.

Older adults with prior adenomas had slightly higher CRC risk, but 10-year CRC incidence was far outweighed by non-CRC mortality, supporting reduced surveillance colonoscopy use.

Nicholas Richardson, DO, MPH, discussed the implications of the FDA’s January draft guidance proposing MRD-negative complete response as a primary end point for accelerated approval in multiple myeloma.

The disease progression of patients with MS had an association with their serum protein level.

Skin cancers arising from burn scars carry high recurrence and mortality risks, with squamous cell carcinoma considered most common.

Bidirectional endoscopy (upper endoscopy and colonoscopy) was underutilized in the evaluation of new-onset iron deficiency anemia in younger veterans from 2005 to 2019.